Jaguar Health (JAGX) Convertible Debt (2017 - 2018)
Jaguar Health (JAGX) reported Convertible Debt of $10.7 million for Q3 2018, down 4.48% year-over-year from $11.2 million in Q3 2017, and down 2.93% quarter-over-quarter from $11.0 million in Q4 2017.
Jaguar Health (JAGX) Convertible Debt (2017 - 2018) Analysis & Trends
Jaguar Health (JAGX) has 2 years of Convertible Debt data on file, last reported at $10.7 million in Q3 2018.
- Convertible Debt for Q3 2018 came in at $10.7 million, down 4.48% year-over-year; the trailing twelve-month figure through Sep 2018 was $10.7 million (down 4.48% YoY), and the FY2017 annual result was $11.0 million, changed N/A from the prior year.
- Convertible Debt retreated to $10.7 million in Q3 2018 per JAGX's latest filing, from $11.0 million in the prior quarter.
- Over five years, Convertible Debt peaked at $11.2 million in Q3 2017 and troughed at $10.7 million in Q3 2018.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Alterity Therapeutics | 723,416.35 Bn | 723,416.32 Bn | - |
| 2 | Belite Bio | 57,340.00 Bn | 57,340.00 Bn | - |
| 3 | Quantum Biopharma | 19,125.08 Bn | 19,125.08 Bn | - |
| 4 | Legend Biotech | 3,262.00 Bn | 3,261.71 Bn | 242.10 Mn |
| 5 | Akari Therapeutics | 1,789.67 Bn | 1,789.67 Bn | - |
| 6 | Evaxion A | 1,480.39 Bn | 1,480.37 Bn | - |
| 7 | Psyence Biomedical | 241.78 Bn | 241.78 Bn | - |
| 8 | Vertex Pharmaceuticals | 113.54 Bn | 106.29 Bn | 2.59 Bn |
| 9 | Abivax | 94.26 Bn | 94.26 Bn | - |
| 10 | Jaguar Health | 1.44 Mn | -10.19 Mn | 19.11 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Sep 30, 2018 | 10.66 Mn |
| Dec 31, 2017 | 10.98 Mn |
| Sep 30, 2017 | 11.16 Mn |